BACKGROUND: Lactose malabsorption (LM) is a very common problem with high prevalence in Southern Europe. The lactose tolerance test (LTT) is a basic probe, which is widespread in local hospitals, because it requires non-complex and inexpensive infrastructure. The aims of our study are to determine that a reduction in the duration of LTT does not affect its diagnostic accuracy to detect LM and to calculate the savings that this reduction may represent. METHODS: A prospective study of consecutive patients who underwent LTT for suspected LM was conducted. We analyzed and compared the clinical results and costs (extraction, analytical measurement, time spent by nursing staff, technicians and patients) of suppressing LTT points at 30 and 120 min. RESULTS: The study included 201 patients. Pathological LTT was found in 119 cases. Eliminating the measurement of glucose at 120 min did not alter the LTT interpretation in any patient; however, up to 18.4% of patients had a LTT misinterpretation when the 30 min point was suppressed. If the LTT 120 min measurement would have been suppressed, 41 334 euros could have been saved. CONCLUSIONS: Suppressing the 120 min LTT point does not imply any changes in clinical results and reduces patient's waiting time; it also benefits the health system by saving time, manpower and materials. 
INTRODUCTION
Lactose is a disaccharide (glucose and galactose) found in milk and in many everyday foods. For its absorption, it requires proper lactase enzyme activity found in the brush borders of the small intestinal mucosa. Lactose malabsorption (LM) is the most common type of carbohydrate malabsorption, the frequency of which varies by ethnicity of the population, with low prevalence in Northern Europe (o5%) compared with Southern Europe (70-80%) and Southeast Asia (nearly 100%). 1, 2 When LM gives rise to symptoms, this is called 'lactose intolerance'. The most common clinical symptoms are abdominal pain, diarrhea, bloating, flatulence and vomiting. 3 However, LM does not always translate into the development of symptoms of intolerance; in fact, only between one third and one half of patients with LM are intolerant. 1 There are different methods for the LM diagnosis, from the measurement of lactase activity through jejunal biopsy, to absorption testing (lactose overload), to malabsorption testing (lactose hydrogen breath test, LHBT) and to fecal testing (fecal pH). 4 Recently, a new genetic test, based on C/T-13910 polymorphism, has been proposed for the diagnosis of adult-type hypolactasia, complementing the role of breath testing, 5 and a new test based on oral administration of 4-galactosylxylose (gaxilose) and urine or serum measurement of D-xylose after cleavage by intestinal lactase is under clinical development. 6 The lactose tolerance test (LTT) is a basic probe, which is widespread in local hospitals, because it requires non-complex and inexpensive infrastructure. It involves measuring blood glucose at different times (baseline, 30 min, 60 min and 120 min) after ingesting 50 g of lactose. Its disadvantages include potential common symptoms, minimally invasive nature (collection of multiple blood tests) and duration (120 min). 7 In recent years, all industrialized countries encountered a problem that has existed for some time: progressive and increasingly limited resources allotted to health care. It is important to know what options will be the most efficient, which will result in greater therapeutic benefits with lower associated costs. 8 Recently, we have observed that the duration of LTT can be shortened without affecting accuracy. This can result in lower costs and time. The main objective of our study is to determine that a reduction in the duration of LTT does not affect diagnostic accuracy to detect LM and to calculate the savings that this reduction may represent.
MATERIALS AND METHODS Subjects
A multicenter, observational and prospective study of consecutive patients, from November 2011 to June 2012, over the age of 16, who underwent LTT for suspected lactose intolerance was conducted. Patients from six Alto Guadalquivir Healthcare Agency hospitals (ASAG, Andalusia, South of Spain) were included. Overall ASAG serves a population of 253 000 inhabitants. Exclusion criteria were: organic disease explaining symptoms (celiac disease, hyper/hypothyroidism and inflammatory bowel disease recurrence), recent intake of antibiotics/probiotics (o30 days), recent use of prokinetic/proton pump inhibitors (o7 days), major abdominal surgery, alcohol abuse 460 g of alcohol per day and diabetes mellitus.
The Institutional Ethics Committee approved the study protocol, and consent was obtained from each subject.
Design
Patients followed a predefined lactose-free diet for 7 days. They were then subjected to LTT, by administration of 50 g/250 ml lactose after fasting (Lactonaranja, Bioanalitica S.L., Madrid, Spain) and blood collection at baseline, 30 min, 60 min and 120 min, respectively. Serum glucose levels (mg/dl) were determined in the cobas 8000 modular analyzer (Roche Diagnostics, Mannheim, Germany). LTT was considered classic (cLTT) when results included the four points from the curve and reduced (rLTT) when results excluded 30 min or 120 min point. Results were deemed positive (pathological malabsorption) when increases in glucose levels do not exceed 20 mg/dl compared with baseline at any time point, which was the most widely accepted cutoff point, 9 and were deemed negative (normal) when at least in one time point the glucose levels increase exceeding 20 mg/dl.
Economic analysis
We analyzed and compared the costs of suppressing LTT at 30 min or 120 min. The direct costs of further extraction were calculated, both in terms of consumables (needles, vacuum systems, biochemistry tubes, cotton and plaster) and staff (nurses and laboratory technicians). The costs of the time lost by the patient (60 min) when subjected to cLTT or rLTT were also calculated.
Statistical method
The sample size was obtained using GRANMO version 7.12 (IMIM, Hospital del Mar, Barcelona, Spain), accepting an alpha risk of 0.01 and a beta risk of 0.1 in a one-sided test; 197 subjects are needed, assuming the initial ratio of events is 0.85 and the end ratio is 0.95. Differences between rLTT and cLTT were analyzed with a McNemar test for paired proportions of two groups. The diagnostic efficacy of the test was calculated by using sensitivity, specificity, positive predictive value and negative predictive value. Differences in blood glucose levels between patients with normal and pathological tests were determined using Student's t-test for comparison of independent means. The PASW Statistics 18.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis (statistical significance: Po0.05).
RESULTS
The study involved a total of 206 patients, excluding 5 who met exclusion criteria (3 type 2 diabetes mellitus, 1 hypothyroidism and 1 adult celiac disease). All patients were white (mean age of 39 ± 16 years; 69.2% were women). Symptoms that prompted the study were abdominal pain (72%), flatulence (54%), diarrhea (52%), abdominal bloating (47%), bowel sounds (24%) and vomiting (13%). In 119 patients (59.2%), LTT was pathological (LM). No statistically significant differences were observed between baseline glucemia in patients with normal or pathological cLTT (P ¼ 0.597); however, (as expected) such differences were observed at other different time points: 30 min (P ¼ 0.03), 60 and 120 min (Po0.0001) (Figure 1) .
Eliminating 120 min point did not alter the interpretation of LTT in any patient; by contrast, up to 18.4% of patients had a misinterpretation of LTT when the 30 min measurement was suppressed (McNemar test: P ¼ 1.00 and Po0.01, respectively). Table 1 shows the diagnostic efficacy of the different rLTT regarding cLTT. Table 2 shows the direct costs saved if the LTT 120 min point was excluded. During 2011, 2267 patients underwent LTT at ASAG; therefore, if the LTT 120 min measurement would have been suppressed, 41 334 euros could have been saved.
DISCUSSION
There are different methods for diagnosing LM. Measurement of lactase activity in jejunal biopsies has been proposed as the 'gold standard'. 9 However, this test is too aggressive for studying mild disease, and the results can be biased by an irregular spreading of lactase activity throughout the mucosa of the small intestine. 1 LHBT is the most commonly used indirect method for the diagnosis of LM, because it is non-invasive, reliable and inexpensive. 10 It has good sensitivity (0.77) and excellent specificity (0.97). 11 However, in addition to requiring 240 min for completion, it is possible to find false negatives due to the inability of the intestinal flora to produce H 2 after ingestion of non-absorbable carbohydrates or after recent antibiotic administration, and false positives caused by bacterial overgrowth. A genetic test has recently been created on the basis of the measurement of C/T-13910 polymorphism in DNA, whose C/C variant has a strong correlation with poor lactase activity; however, its disadvantage is that it is expensive and lacks clinical information that derives from exposure to lactose. 5, 12 Although LHBT is the most and common method cited in the literature, many local hospitals lack the necessary equipment for its use, so LTT is still used. It is a minimally invasive test, which requires 120 min for completion, with a sensitivity of 75% in adults and a specificity of 96%. 13 There are false negatives in patients with diabetes, bacterial overgrowth and delayed gastric emptying. A recent meta-analysis has confirmed the diagnostic validity of the LTT compared with genetic test (C/T-13910 polymorphism) and showed sensitivity of 0.94 (0.9-0.97) and specificity of 0.90 (0.84-0.95). 14 A dosage of 50 g of lactose was used to perform LTT; nevertheless, in a recent report, a more physiological dose of 25 g was utilized, 15 so we recommend this dosage for clinical utilization and for further studies.
In our results, we have observed that rLTT (excluding 120 min) detects the same proportion as cLTT, with 100% of sensitivity, specificity, positive predictive value and negative predictive value. These data are comparable to the study by Montes, 16 designed with different methodology and smaller sample size, but with the same conclusion. Plasma glucose levels reached their maximum after 30 min and have more or less returned back to baseline levels after 120 min. In this way, it does not make sense to try to omit the 30 min time point (as that would make us miss the diagnosis of LM in nearly 20% of patients), whereas it seems logical that the 120 min time point is redundant and not necessary for interpretation. There is hardly any recent literature to endorse these results, because most publications focus on LHBT and other innovative methods.
Economic evaluations in health aim to compare the impact of the intervention on the health of individuals affected by the impact of changes in consumption resource. Suppressing a LTT point (120 min) does not imply any changes in the health of patients, and the clinical results are identical to those obtained when performing cLTT. Direct costs are those that correspond to changes in resources caused by the intervention itself, both health and non-health resources (time lost by the patient). Instead, indirect costs have classically been used to refer to the profit or loss of productivity. In the present case, indirect costs could not be calculated due to complexity, but in any case, there could be further benefits in suppressing the LTT 120 min point. Clearly, the benefits achieved in rLTT are positive for patients preventing taking samples and reducing the waiting time; it also benefits the health system by saving time, manpower and materials. Although the subject of this study is not the comparison of rLTT with other diagnostic methods, it is important to note that the time needed for its realization would be a quarter of the time needed to carry out the LHBT (240 min). Moreover, in patients undergoing LTT, the procedure itself allows obtaining valuable clinical information, an additional advantage not offered by genetic testing and lactase activity in duodenal biopsies. Therefore, based on the data presented, rLTT has economic advantages over cLTT, with which it shares the same diagnostic yield. The present study showed the diagnostic efficacy of the different rLTT compared with cLTT, but not the real diagnostic accuracy of the shortened LTT for determining LM.To definitively validate this shortened LTT, a comparison with genetic test is necessary for further studies in a larger series of patients. 
